Navigation Links
Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD
Date:12/7/2011

REDWOOD CITY, Calif., Dec. 7, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced positive top-line results from a randomized, double-blind, Phase 2b, dose-ranging study of glycopyrrolate, a long-acting muscarinic agonist (LAMA) delivered twice a day (BID) via metered-dose inhaler (GP MDI; PT001) in patients with moderate-to-severe COPD. Four doses of GP MDI were compared to placebo and Atrovent® HFA Inhalation Aerosol, a short-acting muscarinic antagonist given four times a day (QID). All doses of GP MDI tested produced statistically significant improvements in lung function (FEV1 AUC 0-12)(1) compared to placebo (p<0.0001). Further, doses of PT001 were identified that were non-inferior to Atrovent HFA. PT001 was well tolerated and no safety concerns were identified. This study complements Pearl's previous assessment of PT001's clinical profile relative to well established marketed muscarinic antagonists(2), and provides additional dose ranging data for glycopyrrolate component of Pearl's LAMA/LABA combination product, PT003. Detailed results of this Phase 2b study of PT001 will be presented at a future conference.

Dr. Colin Reisner, chief medical officer and executive vice president of clinical development for Pearl Therapeutics commented, "This Phase 2b study provides important information about the safety and efficacy of GP MDI, the LAMA component of PT003, our lead combination bronchodilator candidate for the treatment of COPD. Further, the activity profile of GP MDI in this study is consistent with that observed in two previously reported studies and supports the BID dosing that we believe will provide the best symptom relief for patients with moderate-to-severe COPD."

"A significant part of the very large COPD market is driven by the use of BID LABAs and inhaled corticosteroids.  However, a rapid-acting, BID LAMA to complement these options is not yet available," said Chuck Bramlage, chief executive officer for Pearl Therapeutics. "We believe GP MDI has the clinical profile to fill this treatment gap and become a best-in-class LAMA monotherapy. In addition, GP MDI is a key component of our combination bronchodilator PT003, which, pending the successful completion of our remaining Phase 2b studies, we expect to advance into Phase 3 trials in 2012."

About COPD

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable lung disease that is the fourth leading cause of death in the United States. Each year 12 million Americans are diagnosed with COPD and an additional 12 million Americans may have COPD but remain undiagnosed. Research shows that many do not get optimal treatment.

Bronchodilator medications are central to symptom management and are prescribed on an as-needed or regular basis to prevent or reduce symptoms. Long-acting inhaled bronchodilators have been shown to be most effective and convenient. Combining bronchodilators of different pharmacological classes, as recommended by The Global Initiative for Chronic Obstructive Lung Diseases (GOLD), has been shown to improve efficacy and may decrease the risk of side effects compared to increasing the dose of a single bronchodilator. As the course of COPD progresses, regular treatment with inhaled glucocorticosteroids may be added to bronchodilator treatment.

About Pearl Therapeutics

Pearl Therapeutics is a privately held company developing inhaled combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease and asthma. Pearl is rapidly advancing a pipeline of products including PT003, an inhaled, fixed-dose combination bronchodilator product comprised of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI); and PT010, a triple-combination product that combines the LAMA and LABA components of PT003 with an inhaled corticosteroid (ICS) for twice-daily administration from an HFA MDI for the treatment of severe COPD. Both PT003 and PT010 are developed with Pearl's proprietary porous particle cosuspension technology, which allows the formulation of multiple products in the MDI format, with highly stable, robust and aerodynamically efficient drug delivery. Founded in 2006, Pearl Therapeutics is privately held and backed by 5AM Ventures, Clarus Ventures, New Leaf Ventures and Vatera Healthcare. For more information, please visit www.pearltherapeutics.com.

(1) FEV1 (forced expiratory volumes in one second) is a common measurement of lung function in patients with asthma, cystic fibrosis, and COPD and is typically used to predict the severity of pulmonary disease. AUC (area under the curve) is a measure of therapeutic benefit over a period of time.

(2) Previously, Pearl has reported a comparative assessment of PT001 relative to Spiriva®, a long-acting, once-a-day, muscarinic antagonist.  See announcements dated May 18, 2010 and January 6, 2010 for more information.

Editor's note: Atrovent® HFA (Ipratropium Bromide) and Spiriva® HandiHaler® (tiotropium bromide inhalation powder) are registered trademarks of Boehringer Ingelheim Pharmaceuticals.


'/>"/>
SOURCE Pearl Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform
2. Anthera Announces Last Patient Enrolled in PEARL-SC Study
3. Pearl Therapeutics Bronchodilator Combination PT003 Provides Superior Inspiratory Capacity Compared to Spiriva®
4. Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
5. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
6. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
7. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
8. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
9. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
10. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
11. Echo Therapeutics to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016 AAIPharma Services Corp./Cambridge Major Laboratories, ... and development services for the pharmaceutical and biotechnology ... capacity in its Charleston, SC ... several recent investments. Charleston ... line with small-scale lyophilization. The site has invested ...
(Date:2/11/2016)... ANKENY, Iowa , 11 de fevereiro de ... a inauguração de sua fábrica de soroalbumina bovina ... Nova Zelândia. A fábrica fica na Ilha Norte ... Loop "), desenvolvido e estabelecido na fábrica da ... Iowa . O projeto e instalação dos ...
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets ... (APAC) breast cancer market will experience considerable expansion ... at a Compound Annual Growth Rate (CAGR) of 8.5%. ... - states that the Asia-Pacific ... billion in 2014 to $3.4 billion by 2021, at a ...
Breaking Medicine Technology:
(Date:2/12/2016)... , ... February 12, 2016 , ... Donor Network West, ... California and Nevada, announced a partnership with San Ramon Regional Medical Center. Under the ... hospital’s facilities as a way to accommodate a more certain time frame for donor ...
(Date:2/12/2016)... TX (PRWEB) , ... February 12, 2016 , ... ... of southwest Houston and surrounding communities by continuing it’s commitment to act as ... Family Promise. The organization works closely with area homeless families to fulfill immediate ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... Strategies for Health Plans and PBMs,” an upcoming Feb. 24 webinar that will ... access in big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi ...
(Date:2/12/2016)... ... February 12, 2016 , ... A lot has been ... years. A president has access to health and wellness resources most Americans could ever ... no single individual has a schedule as frenetic as the U.S. President. , ...
(Date:2/12/2016)... ... February 12, 2016 , ... The aging population ... of long term care. With that, says Patrick Loughney, president of Longtree ... roles in long term care environments. His company, which offers prep courses and ...
Breaking Medicine News(10 mins):